COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

11.90 -0.05 (-0.42%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

33 34 Next >

Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More ↗

January 26, 2024

Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and online course available.

Via Benzinga

New Study Reveals Suggestibility's Role In Antidepressant Effects Of Psilocybin Therapy ↗

January 25, 2024

Study found that suggestibility did not predict response to psilocybin therapy for MDD patients, challenging concerns about placebo effects.

Via Benzinga

Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More ↗

January 15, 2024

Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.

Via Benzinga

5 Largest Psychedelic Drug Stocks Advanced Slightly Last Week ↗

January 13, 2024

The munKNEE Psychedelic Drug Stocks Index went up 2.3% last week and is now up 1.8% MTD.

Via Talk Markets

How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition

January 24, 2024

EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END

Via FinancialNewsMedia

Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More ↗

January 12, 2024

Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD

Via Benzinga

Therapy’s New Frontier: 3 Psychedelic Stocks for the Mental Health Revolution ↗

January 09, 2024

Psychedelic stocks have been making big moves beneath the surface, and the sector's popularity might spark again in 2024.

Via InvestorPlace

3 Big New Catalysts for Psychedelics Stocks in 2024 ↗

January 08, 2024

This could be the year that psychedelics stocks start to fly.

Via The Motley Fool

Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More ↗

January 07, 2024

Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury

Via Benzinga

Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD ↗

January 06, 2024

A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Pub

Via Benzinga

Mental Health Treatment: Compass Pathways And Greenbrook TMS Join Forces For Psilocybin Therapy Research ↗

January 05, 2024

Biotechnology company Compass Pathways plc (NASDAQ: CMPS) and Greenbrook TMS Inc (NASDAQ: GBNH) have entered into a three-year research collaboration agreement to explore delivery models

Via Benzinga

AMA's Reimbursement Codes For Psychedelic-Assisted Therapies Take Effect: Here's What To Expect ↗

January 03, 2024

The American Medical Association’s new coverage and reimbursement codes for FDA-legalized psychedelic-assisted therapies, the current procedural terminology (CPT) III codes, have become active for...

Via Benzinga

Psychedelic Stock Gainers And Losers From January 1, 2024 ↗

January 01, 2024

Via Benzinga

Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More ↗

December 27, 2023

President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also...

Via Benzinga

Psychedelic Drug Stocks Index Up In December; Down YTD ↗

December 27, 2023

The constituents in the Index are up 9.1% MTD, on average, are down 29.2% YTD, on average, and are now down 85.9% from their highs in 2021.

Via Talk Markets

Do Psychedelic Treatments Always Require Psychotherapy? Well, We Need To Look 'Beyond Reductionism' ↗

December 19, 2023

The question of whether psychedelic treatments always require psychotherapy is one hotly debated among researchers, and answers -as well as backstories- vary throughout the whole spectrum.

Via Benzinga

Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More ↗

December 18, 2023

Biden To Decide On Psychedelic Therapy Bill

Via Benzinga

Psychedelic Drug Stocks Index Declined 1.6% This Week ↗

December 17, 2023

Our Psychedelic Drug Stocks Index is now down 11.5% YTD. The AdvisorShares Psychedelic ETF (PSIL), in comparison, remains down 28.8% YTD.

Via Talk Markets

Topics ETFs

Compass Pathways: A Higher-Risk But Potentially Higher-Reward Company In The Biotech Arena ↗

December 16, 2023

If you can afford it – and if it would not be too big a position in your portfolio – putting $2,000 into a couple of speculative biotechs might be a good idea here. One I like is Compass Pathways.

Via Talk Markets

Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More ↗

December 11, 2023

John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy

Via Benzinga

5 Largest Psychedelic Compound-Based Drug Stocks Up 3% Last Week ↗

December 10, 2023

The 5 constituents in our Psychedelic Drug Stocks Index jumped 30.2%, on average, in November and were up a further 2.8% last week.

Via Talk Markets

Compass Pathways appoints Teri Loxam as Chief Financial Officer

December 07, 2023

From Compass Pathways

Via GlobeNewswire

Alternative Treatment For Bipolar II Depression: Psilocybin Safe And Effective, AMA Study Finds ↗

December 06, 2023

A COMPASS Pathways (NASDAQ: CMPS)-backed clinical trial assessing psilocybin-assisted psychotherapy for bipolar II disorder has provi

Via Benzinga

Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry

December 06, 2023

Believed to be first ever psilocybin clinical trial for treatment of bipolar II depression

From Compass Pathways

Via GlobeNewswire

Investing in Mental Health: 3 Stocks in the Wellness Space ↗

December 05, 2023

Mental health stocks can be a great addition to your portfolio as its importance becomes increasingly recognized.

Via InvestorPlace

Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More ↗

December 05, 2023

Defense Dept. Funds Ketamine Study For PTSD Treatment

Via Benzinga

November Recap: Psychedelic Drug Stocks Index Driven 30% Higher By Incannex ↗

December 02, 2023

The 5 constituents in the Psychedelic Drug Stocks Index had declined 46.5% over the past 3 months but jumped 30% in November.

Via Talk Markets

La-Z-Boy Posts Upbeat Earnings, Joins Victoria's Secret, Snowflake And Other Big Stocks Moving Higher On Thursday ↗

November 30, 2023

U.S. stocks traded mostly higher, with the Dow Jones index gaining around 200 points on Thursday.

Via Benzinga

Topics Stocks

Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More ↗

November 24, 2023

GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan

Via Benzinga

Topics Cannabis

GH Research, Compass Pathways Among Top Psychedelic Movers Of Today ↗

November 23, 2023

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

33 34 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.